Potential loss of prognostic significance of minimal residual disease assessment after R-CHOP-based induction in elderly patients with mantle cell lymphoma in the era of rituximab maintenance
Jazyk angličtina Země Velká Británie, Anglie Médium print-electronic
Typ dokumentu klinické zkoušky, časopisecké články, multicentrická studie, pozorovací studie
Grantová podpora
PROGRES Q26/LF1
Ministry of Education, Youth, and Sports
PROGRES Q28/LF1
Ministry of Education, Youth, and Sports
NPU I nr. LO1604
Ministry of Education, Youth, and Sports
AZV 17-28980A (All rights reserved)
Ministry of Health of the Czech Republic
00064203
University Hospital Motol
CZ.2.16/3.1.00/24505
EU-Prague
GAUK 20214
Grant Agency of Charles University
UNCE/MED/016
Charles University Center of Excellence
PubMed
30129045
DOI
10.1002/hon.2550
Knihovny.cz E-zdroje
- Klíčová slova
- PET-CT, elderly patients, maintenance rituximab, mantle cell lymphoma, minimal residual disease,
- MeSH
- cyklofosfamid aplikace a dávkování MeSH
- doxorubicin aplikace a dávkování MeSH
- lidé středního věku MeSH
- lidé MeSH
- lymfom z plášťových buněk * krev farmakoterapie mortalita MeSH
- míra přežití MeSH
- myší monoklonální protilátky aplikace a dávkování MeSH
- následné studie MeSH
- prednison aplikace a dávkování MeSH
- přežití bez známek nemoci MeSH
- protokoly protinádorové kombinované chemoterapie aplikace a dávkování MeSH
- reziduální nádor MeSH
- rituximab aplikace a dávkování MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- udržovací chemoterapie * MeSH
- vinkristin aplikace a dávkování MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- klinické zkoušky MeSH
- multicentrická studie MeSH
- pozorovací studie MeSH
- Názvy látek
- cyklofosfamid MeSH
- doxorubicin MeSH
- myší monoklonální protilátky MeSH
- prednison MeSH
- R-CHOP protocol MeSH Prohlížeč
- rituximab MeSH
- vinkristin MeSH
Rituximab maintenance (RM) prolongs survival of elderly patients with mantle cell lymphoma (MCL). Persistent minimal residual disease (MRD) after induction repeatedly correlated with shorter progression-free survival (PFS). However, none of the published studies analyzed patients treated with RM. The main purpose was to analyze prognostic significance of MRD in the elderly patients with newly diagnosed MCL treated according to the recently published observational trial protocol (alternation of R-CHOP and R-cytarabine, 3 + 3 cycles, GovTrial number NCT03054883) at the centers that implemented RM. Minimal residual disease was evaluated by a EuroMRD standardized real-time PCR approach after 3 and 6 cycles of the induction therapy. Prognostic significance of MRD was analyzed in a subcohort of patients treated at the centers that implemented RM as a standard approach. Bone marrow proved to be a significantly more sensitive source for MRD detection than peripheral blood. In either compartment MRD (positive versus negative) after 3 or 6 cycles of the induction therapy did not correlate with PFS. The observed loss of prognostic significance of MRD after the R-CHOP-based induction appears to be a consequence of RM immune control over the residual lymphoma.
1st Medical Department Charles University General Hospital Prague Czech Republic
Department of Hematology and Oncology Masaryk University Hospital in Brno Czech Republic
Citace poskytuje Crossref.org
Advances in Molecular Biology and Targeted Therapy of Mantle Cell Lymphoma
